CA2903252C - Ribotoxin molecules derived from sarcin and other related fungal ribotoxins - Google Patents

Ribotoxin molecules derived from sarcin and other related fungal ribotoxins Download PDF

Info

Publication number
CA2903252C
CA2903252C CA2903252A CA2903252A CA2903252C CA 2903252 C CA2903252 C CA 2903252C CA 2903252 A CA2903252 A CA 2903252A CA 2903252 A CA2903252 A CA 2903252A CA 2903252 C CA2903252 C CA 2903252C
Authority
CA
Canada
Prior art keywords
sarcin
modified
molecule
ribotoxin
wild type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2903252A
Other languages
English (en)
French (fr)
Other versions
CA2903252A1 (en
Inventor
Kurt R. Gehlsen
Timothy David Jones
Francis Joseph Carr
Arron HEARN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of CA2903252A1 publication Critical patent/CA2903252A1/en
Application granted granted Critical
Publication of CA2903252C publication Critical patent/CA2903252C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/2701—Endoribonucleases producing 3'-phosphomonoesters (3.1.27) rRNA endonuclease (3.1.27.10)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2903252A 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins Active CA2903252C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361783589P 2013-03-14 2013-03-14
US61/783,589 2013-03-14
US201361902972P 2013-11-12 2013-11-12
US61/902,972 2013-11-12
PCT/US2014/020035 WO2014158770A1 (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Publications (2)

Publication Number Publication Date
CA2903252A1 CA2903252A1 (en) 2014-10-02
CA2903252C true CA2903252C (en) 2023-01-17

Family

ID=51625052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903252A Active CA2903252C (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Country Status (11)

Country Link
US (2) US9603911B2 (enExample)
EP (1) EP2971038B1 (enExample)
JP (1) JP6203372B2 (enExample)
AU (1) AU2014241891B2 (enExample)
CA (1) CA2903252C (enExample)
DK (1) DK2971038T3 (enExample)
ES (1) ES2765302T3 (enExample)
PL (1) PL2971038T3 (enExample)
PT (1) PT2971038T (enExample)
SI (1) SI2971038T1 (enExample)
WO (1) WO2014158770A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603911B2 (en) * 2013-03-14 2017-03-28 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2020118192A1 (en) * 2018-12-07 2020-06-11 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
US8114969B2 (en) 2003-10-01 2012-02-14 Isis Innovation, Ltd. Immunotoxin derived from a recombinant human autoantibody and method of using thereof
WO2006076417A1 (en) 2005-01-12 2006-07-20 Proteonova, Inc. Method for making targeted therapeutic agents
US9603911B2 (en) * 2013-03-14 2017-03-28 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Also Published As

Publication number Publication date
WO2014158770A1 (en) 2014-10-02
US9976131B2 (en) 2018-05-22
SI2971038T1 (sl) 2020-02-28
CA2903252A1 (en) 2014-10-02
EP2971038A1 (en) 2016-01-20
DK2971038T3 (da) 2020-01-27
PT2971038T (pt) 2020-01-20
EP2971038A4 (en) 2016-11-23
US9603911B2 (en) 2017-03-28
AU2014241891A1 (en) 2015-09-17
PL2971038T3 (pl) 2020-04-30
AU2014241891B2 (en) 2017-09-14
ES2765302T3 (es) 2020-06-08
JP6203372B2 (ja) 2017-09-27
US20160106819A1 (en) 2016-04-21
JP2016512251A (ja) 2016-04-25
EP2971038B1 (en) 2019-12-04
US20170204387A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
JP7442879B2 (ja) Ｍｈｃクラスｉエピトープ送達ポリペプチド
US11976101B2 (en) Multi-level specific targeting of cancer cells
JP3755773B2 (ja) 変異型ｒドメインを有するジフテリア毒素ワクチン
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
TW201100095A (en) Antigen presenting cell targeted cancer vaccines
US9976131B2 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CA2914555A1 (en) Single domain antibody display
Marshall et al. Engineering and characterization of a novel fusion protein incorporating B7. 2 and an anti–ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
EP2533811A2 (en) Multimeric proteins comprising immunoglobulin constant domains
WO2017053290A1 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
Habibi et al. Expression of a chimeric protein containing the catalytic domain of shiga-like toxin and human granulocyte macrophage colony-stimulating factor (Hgm-csf) IN Escherichia coli and its recognition by reciprocal antibodies
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190226

EEER Examination request

Effective date: 20190226

EEER Examination request

Effective date: 20190226

EEER Examination request

Effective date: 20190226